Trials / Unknown
UnknownNCT00703235
Intravitreal Bevacizumab for Diabetic Macular Edema
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Isfahan Ophthalmology Research Center · Network
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab |
Timeline
- First posted
- 2008-06-23
- Last updated
- 2008-06-23
Source: ClinicalTrials.gov record NCT00703235. Inclusion in this directory is not an endorsement.